Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 04 December 2012 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) is delaying by two weeks the implementation of its facility registration requirements under the Generic Drug User Fee Act (GDUFA), a subset of a recently passed FDA Safety and Innovation Act (FDASIA).
One of the law's main goals was to achieve parity between the way FDA collects fees from branded and generic pharmaceutical products. Under a long-standing program, FDA assesses user fees from branded pharmaceutical companies in return for it spending that money on new review staff and otherwise upgrading its capacity to regulate products efficiently. Industry is generally in favor of this, as it speeds up the time it takes for its products to be reviewed by regulators.
FDASIA extends this program to the generic drug industry under GDUFA, calling on generic drug manufacturers to pay a yearly fee to register its manufacturing facilities, among other fees and changes. The due date for those registrations to have been received by FDA was 3 December 2012, but now FDA says it will grant a two-week grace period for all remaining facility registrations to be received by agency officials.
After that grace period is up, it writes, all products manufactured by those facilities will be considered "misbranded."
A generic drug "facility" is a fairly broad term under the act, encompassing any place that manufactures products, finishes, packages, re-packages or labels the product, as well as any organization that conducts bioequivalence or bioavailability testing on generic products and other testing sites.
Those facilities should supply FDA with the name of the registrant owner, the name of the facility owner, the name of the company, the type of business operation they are running, their DUNS number, their Facility Establishment Identifier (FEI) and the address where their facility is located. Only certain facilities will be required to pay facility fees, but all are required to register with FDA.
"This self-identification information will assist in constructing an accurate inventory of facilities, sites and organizations involved in the manufacture of generic drugs," FDA wrote in a Federal Register posting on 1 October 2012. Any facilities not providing FDA with the required information are subject to prosecution, injunctions and product seizures, as well as products being denied entry into the US.
FDA said more than 1,700 generic drug facilities have already registered with FDA-"below estimates of the universe of generic drug facilities." An FDA analysis of recent Abbreviated New Drug Applications (ANDAs) and Prior Approval Supplements (PASs) found that roughly one in eight applicants had failed to self identify with FDA-a trend the agency said would "result in higher individual facility fee amounts" for those who had registered.
"FDA does not want to penalize companies that have already complied with this new requirement by setting higher annual facility fee rates based on an artificially low industry reporting base," it explained, saying it hopes the two-week grace period gives the remaining facilities time to register.
Tags: Extended, Deadline, Facility, Generic, pharmaceutical, registration, drug, GDUFA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.